{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:58:02Z","timestamp":1792796282521,"version":"4.5.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC-3105\/1 \u2013 533765739"],"award-info":[{"award-number":["EXC-3105\/1 \u2013 533765739"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC-3105\/1 \u2013 533765739"],"award-info":[{"award-number":["EXC-3105\/1 \u2013 533765739"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic disorder closely linked to cardiometabolic risk and dysregulated lipid metabolism. Apolipoprotein C3 (ApoC3), a key regulator of triglyceride-rich lipoproteins and mediator of cardiovascular disease, has been implicated in hepatic steatosis. However, its stage-specific role across the MASLD spectrum remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cohort study, serum ApoC3 concentrations were quantified in 197 patients with MASLD across different disease stages (non-fibrotic MASLD, fibrosis, cirrhosis, and cirrhosis with hepatocellular carcinoma (HCC)) and compared with 204 blood donor controls. Associations with metabolic parameters, non-invasive fibrosis markers, histology, cardiometabolic comorbidities, and genetic risk variants were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ApoC3 levels exhibited a stage-dependent pattern, with significantly lower concentrations in cirrhotic MASLD and HCC compared to non-fibrotic MASLD and controls (median 18.7 vs. 26.6 vs. 27.4 mg\/dL, p\u2009&lt;\u20090.05). Lower ApoC3 levels were associated with markers of advanced liver disease, including higher bilirubin, liver stiffness, Fibrosis-4 index, and NAFLD fibrosis score. In contrast, higher ApoC3 levels were observed in early-stage MASLD and were associated with cardiometabolic comorbidities and dyslipidemia. ApoC3 correlated positively with triglycerides (r\u2009=\u20090.485, p\u2009&lt;\u20090.001) and controlled attenuation parameter values (r\u2009=\u20090.274, p\u2009=\u20090.004), and was highest in patients with severe steatosis (S3) and increased inflammatory activity (NAS\u2009\u2265\u20095). Diagnostic performance for cirrhosis was modest (AUC 0.642) and for HCC 0.673.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ApoC3 demonstrates a biphasic, stage-dependent profile in MASLD, with elevated levels reflecting hepatic steatosis, and metabolic dysfunction in early disease, and declining levels likely indicating impaired hepatic function in advanced stages. These findings position ApoC3 as a link between hepatic lipid accumulation and cardiovascular risk rather than a linear marker of disease severity. Its clinical utility may lie in integrative, multi-parameter models rather than as a standalone biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0349666","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:29:46Z","timestamp":1782235786000},"page":"e0349666","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6420-3549","authenticated-orcid":true,"given":"Eva Katharina","family":"Messer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janett","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Herta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Boehlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Matz-Soja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Tuennemann-Tarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"pone.0349666.ref001","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"ZM Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"pone.0349666.ref002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"pone.0349666.ref003","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"LA Adams","year":"2017","journal-title":"Gut"},{"issue":"10","key":"pone.0349666.ref004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"GD Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"pone.0349666.ref005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/ATVBAHA.110.221846","article-title":"Apolipoprotein CIII: 42 years old and even more interesting","volume":"31","author":"HN Ginsberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"pone.0349666.ref006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713288","article-title":"Advances in treatment of dyslipidemia","volume":"24","author":"J Dybiec","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"pone.0349666.ref007","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1194\/jlr.M500455-JLR200","article-title":"Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism","volume":"47","author":"J-F Mauger","year":"2006","journal-title":"J Lipid Res"},{"issue":"2","key":"pone.0349666.ref008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1871529X11202020133","article-title":"Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins","volume":"12","author":"Z Yao","year":"2012","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"1","key":"pone.0349666.ref009","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12944-020-01293-9","article-title":"Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study","volume":"19","author":"JL Katzmann","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"23","key":"pone.0349666.ref010","doi-asserted-by":"crossref","first-page":"12759","DOI":"10.3390\/ijms252312759","article-title":"Multifaceted role of apolipoprotein C3 in cardiovascular disease risk and metabolic disorder in diabetes","volume":"25","author":"B-Y Pan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0349666.ref011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12944-024-02389-2","article-title":"Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials","volume":"24","author":"A Mahmoud","year":"2025","journal-title":"Lipids Health Dis"},{"key":"pone.0349666.ref012","article-title":"Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome","author":"GG Schwartz","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"pone.0349666.ref013","first-page":"108","article-title":"Uncovering the role of apolipoprotein C-III in insulin resistance","volume":"33","author":"D Aguilar-Recarte","year":"2021","journal-title":"Clin Investig Arterioscler"},{"issue":"6","key":"pone.0349666.ref014","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1747493018778713","article-title":"Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke","volume":"13","author":"From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO)","year":"2018","journal-title":"Int J Stroke"},{"issue":"5","key":"pone.0349666.ref015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"T Bo","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"pone.0349666.ref016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jacl.2020.10.006","article-title":"Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes","volume":"15","author":"T Buckner","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"1","key":"pone.0349666.ref017","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-022-02822-w","article-title":"Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis","volume":"24","author":"C Mart\u00edn-Gonz\u00e1lez","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"pone.0349666.ref018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0349666.ref019","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"PN Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"pone.0349666.ref020","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"pone.0349666.ref021","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"S McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"pone.0349666.ref022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"C Bianco","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0349666.ref023","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"pone.0349666.ref024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"WJ Youden","year":"1950","journal-title":"Cancer"},{"issue":"3","key":"pone.0349666.ref025","doi-asserted-by":"crossref","first-page":"101300","DOI":"10.1016\/j.jhepr.2024.101300","article-title":"Non-invasive assessment of portal hypertension: Liver stiffness and beyond","volume":"7","author":"M Mandorfer","year":"2024","journal-title":"JHEP Rep"},{"issue":"1","key":"pone.0349666.ref026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1194\/jlr.M900346-JLR200","article-title":"Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions","volume":"51","author":"M Sundaram","year":"2010","journal-title":"J Lipid Res"},{"issue":"8","key":"pone.0349666.ref027","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"JS Cohn","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0349666.ref028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis","volume":"9","author":"MC Wyler von Ballmoos","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"6","key":"pone.0349666.ref029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4254\/wjh.v6.i6.435","article-title":"Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: a pilot study","volume":"6","author":"VVR Kanth","year":"2014","journal-title":"World J Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:29:54Z","timestamp":1782235794000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349666"}},"subtitle":[],"editor":[{"given":"Pavel","family":"Strnad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349666","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}